Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

150 Days: Obama's Silence On AIDS Remains Deafening
On the observation of President Obama"s first 150 days in office, AIDS Healthcare Foundation (AHF), the nation"s largest AIDS organization, is continuing its "Change AIDS Obama" campaign with the release of a new online advocacy video chastising the president for his ongoing-and baffling-silence on AIDS.
generic viagra online
'Super-Recognizers,' With Extraordinary Face Recognition Ability, Never Forget A Face
Some people say they never forget a face, a claim now bolstered by psychologists at Harvard University who"ve discovered a group they call "super-recognizers": those who can easily recognize someone they met in passing, even many years later.
News of the day
Gene Discovery Suggests Cancer Drugs Might Treat Alcoholism
A class of drugs already approved as cancer treatments might also help to beat alcohol addiction. That"s the conclusion of a discovery in flies of a gene, dubbed happyhour, that has an important and previously unknown role in controlling the insects" response to alcohol.
Endocrinology

Gilead Sciences, Tibotec To Develop Second Once-Daily HIV Treatment

Foster City, Calif.-based Gilead Sciences on Thursday said it has entered into a license and collaboration agreement with Johnson and Johnson subsidiary Tibotec Pharmaceuticals for the development and commercialization of a new once-daily fixed-dose treatment for HIV, the San Francisco Business Times reports. The FDA approved the first once-daily HIV treatment Atripla in 2006 (7/16). The new antiretroviral drug would contain Tibotec"s experimental non-nucleoside reverse transcriptase inhibitor, known as TMC278, and Gilead"s combination pill, Truvada. Kevin Young, head of commercial operations at Gilead "said the new combination pill, along with Gilead"s experimental "quad" pill, will be used for newly-diagnosed patients, with physicians reluctant to change therapy for patients who are responding well to Atripla," Reuters reports. Young said the drug is expected to reach the market in 2011 (Beasley, 7/16). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009